glp 1 receptor drugs GLP-1 Agonists and Research to Treat Overeating and Substance Use Disorders Frontiers | GLP−1 receptor agonists
Description
109 , e1608e1615 (2024)
Mundil, D., Cameron-Vendrig, A
Disclaimer This content is not medical advice
ABSTRACT: The past decade has brought several new developments in the treatment of type 2 diabetes, including the glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
The incidence of antibody formation was 44% with exenatide, 8.6% with liraglutide, 69.8% with lixisenatide, 4% with albiglutide, and 1.6% with dulaglutide [48, 103-106]
TimmersLHenriquesJPde KleijnDPDevriesJHKempermanHSteendijkPet alExenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
